BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts, on March 7, 2023. Management will also be available for 1-on-1 meetings with investors. 43rd Annual Cowen Health Care Conference Presentation Details Fireside Chat: Tuesday, March 7th, 2023, at 2:10 PM ET Speaker: David…

BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that management is scheduled to participate at the LifeSci Partners 12th Annual Corporate Access Event being held during the week of the J.P. Morgan Healthcare Conference, in San Francisco, CA and will be available for one-on-one meetings. One-on-One Meeting Details Meeting Dates: January 10-11, 2023 Location: Beacon Grand Hotel Format: 1-on-1, in-person meetings *For more information or to request a meeting please register here About VYNE…

BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it will hold a virtual Key Opinion Leader (KOL) event on VYNE’s InhiBET™ BET Inhibitor Platform on Tuesday, May 17, 2022 at 10:00 a.m. ET. The agenda for the webinar will include an overview on pan-bromodomain and extra-terminal (“BET”) inhibition for the treatment of various immuno-inflammatory conditions, a review of the current treatment landscape and unmet medical need in treating patients with vitiligo, a discussion…

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at LifeSci Partners’ virtual Immunology and Inflammation Symposium, taking place May 10th-11th, 2022. Virtual Presentation Details     Date: Tuesday, May 10th Time: 1:30pm Eastern Time Webcast Link: VYNE Therapeutics Presentation The replay of the webcast will be available on the VYNE website for 90 days following the conference. About VYNE…